Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study is a research paper published in The Oncologist (2021). On theSindex it has a DataRank of 1.5. It has been cited 43 times, with 34 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.568
From this paper's citation signal
Citation Network Contribution
0.927
From 28 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 34 citers.
NCI NIH HHS
Grant: T32 CA217834
NCI NIH HHS
Grant: F32 CA254070
NCI NIH HHS
Grant: K23 CA204726
Fields of Study
MeSH Terms
Keywords